Brind.

The implementation of the Medicare Part D model is affecting sales for BioTech companies.

1 report, 1 independent Updated Aug 4

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

BioTech

How it developed

Newest first. Tap a step to see who reported it.

Jul 18Enrollment in Medicare Part D affects drug cost coverage.Sub-event
Aug 4Medicare Part D model implementation is impacting sales figures in the biotech sector.1 source
- Zacks

Keep exploring

The entities involved

BioTech
company in Prague, Czechia
- PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.Sun 13:48

Coverage

Newest first; wire copies grouped

Aug 4ZacksGILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock? Biotech bigwig Gilead Sciences, Inc. (GILD) is scheduled to report second-quarter 2025 results on Aug. 7, after market close. The Zack